EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces its audited final results for the year ended 31 December 2011, a year of continued progress.
EKF Diagnostics has been awarded a contract in Mexico for 3,500 HemoPoint H2 haemoglobin testing devices.
EKF Diagnostics Holdings plc announces its unaudited interim results for the six month period ended 30 June 2011, a period of transition, investment and progression.
EKF Diagnostics announces that it has entered into a conditional distribution agreement with Alere Inc.
Proposed acquisition of the entire issued share capital of Stanbio Laboratory L.P.
Quotient Diagnostics has received approval from China’s SFDA for its Quo-Test A1C test.